FALLS CHURCH, VA – October 26, 2015 – Paul A. Gurbel, MD, world-renowned interventional cardiologist and researcher, is joining Inova Heart and Vascular Institute (IHVI), located on the Inova Fairfax Medical Campus, as the Director of Interventional Cardiology and Cardiovascular Medicine Research. He has already begun working for IHVI part time, and joins full time on November 1.

Dr. Gurbel comes to Inova from Sinai Hospital of Baltimore, where he served as the Director of Cardiovascular Research and the Director of the Sinai Center for Thrombosis Research, which he founded in 1997. He is also a Professor of Medicine at the Johns Hopkins University School of Medicine and Adjunct Professor of Medicine at Duke University School of Medicine.

Dr. Gurbel joins recent IHVI recruit Charles Murphy, MD, from Duke University, who serves as the chief safety officer and cardiovascular intensivist, as Inova moves to transform its cardiovascular leadership.

Dr. Gurbel’s research focuses on the effects and development of antiplatelet agents. His laboratory pioneered the concept of antiplatelet response variability, and his research and observations led to the development of new P2Y₁₂ inhibitors. Dr. Gurbel’s lab also instituted personalized antiplatelet therapy based on phenotypic and genetic analyses. He holds patents in the fields of interventional cardiology and antithrombotic therapy.

“Dr. Gurbel is a true leader in the advancement of interventional cardiology through innovative research on thrombosis and bleeding.,” said Christopher M. O’Connor, MD, Chief Executive Officer, IHVI. “We look forward to working with him to establish a center of excellence in treating complex coronary artery disease and expanding our thrombosis research.”

“It is a great honor for my team and me to join Inova’s world-class heart and vascular program,” said Dr. Gurbel. The standard of excellence that is omnipresent at this institution will definitely lead to major advances in our clinical and research programs. We are so excited to be part of the team at this visionary medical center.”

Inova and Sinai Hospital have agreed to work together to advance the treatment of congestive heart failure throughout the mid-Atlantic region. Dr. Gurbel will continue to be available to treat patients in Baltimore and Virginia.

Dr. Gurbel earned his medical degree at the University of Maryland School of Medicine and completed an internship and residency in Internal Medicine at Duke University Medical Center. He then completed a fellowship in Pulmonary and Critical Care at Johns Hopkins University, followed by fellowships in Cardiovascular Disease and Interventional Cardiology as well as a Chief Residency in internal medicine at Duke. He is board-certified in internal medicine, cardiovascular disease and interventional cardiology by the American Board of Internal Medicine.

Media Contacts: Tracy Connell, tracy.connell@inova.org

# # #About Inova

Inova is a not-for-profit healthcare system based in Northern Virginia that serves more than 2 million people each year throughout the Washington, DC, metro area and beyond. Inova is a comprehensive network of hospitals, outpatient services and facilities, primary and specialty care practices, and health and wellness initiatives.

Inova encompasses the full array of health services, including the area’s only Level 1 Trauma Center and Level 4 neonatal intensive care unit. We are home to many nationally and internationally recognized programs, including Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute (ITMI), Inova Dwight and Martha Schar Cancer Institute (ISCI).

 

Inova is a global leader in the science of genomics and the new era of personalized health, which uses a person’s genetic make-up, family and medical history, and lifestyle to determine the best prevention and treatment. We connect researchers, clinicians and empowered consumers to improve patient care, enhance prevention and encourage wellness.